TSX Shariah screener · October 2026
Is MediPharm Labs Corp. (LABS) Halal?
MediPharm Labs Corp. · TSX: LABS · Healthcare
The short answer
MediPharm Labs Corp. (TSX: LABS) is a FAIL in our October 2026 screen. The business gate fails: it is a pharmaceutical-grade cannabis company and about 15% of Q2 2026 revenue (C$1.5M of C$10.0M) came from Canadian adult-use (recreational) cannabis, above the ~5% de-minimis screen. The debt and income gates are moot: the company is virtually debt free with C$9.9M cash.
Gate 1 — Business activity: FAIL
MediPharm Labs is a pharmaceutical company specialized in precision-based cannabinoids: GMP-certified extraction, purified concentrates and APIs, and derivative products (Barrie, Ontario), plus Beacon Medical subsidiaries in Germany and Australia and Harvest Medicine clinics. Q2 2026 net revenue was C$10.0M (+11% quarter over quarter), split approximately 58% international medical cannabis (C$5.8M), 23% Canadian medical (C$2.3M) and ~15% Canadian adult-use + wellness (C$1.5M); the company says over 80% of revenue comes from regulated medical channels. Adult-use cannabis is recreational cannabis: ~15% of revenue is materially above a ~5% de-minimis screen, and cannabis — across medical and adult-use channels — is the company's core business, not a side line. Facts only.
Gate 2 — Debt and cash: PASS (moot)
The Q2 2026 release describes the company as virtually debt free, with C$9.9M cash and outright ownership of two production facilities appraised at over C$15M. Debt is therefore approximately 0% of the ~C$29.9M market cap (C$0.07). This gate is moot: the screen already fails on the business gate. Facts only.
Gate 3 — Non-compliant income: Not disclosed (moot)
Interest income is not separately disclosed in the Q2 2026 materials reviewed. This gate is moot: the screen already fails on the business gate. Facts only.
Key figures used
- Q2 2026 net revenue C$10.0M (+11% vs Q1 2026); positive net income vs C$3.8M net loss in Q2 2025; Adjusted EBITDA C$0.9M.
- Revenue mix (Q2 2026): international medical cannabis ~58% (C$5.8M), Canadian medical ~23% (C$2.3M), Canadian adult-use + wellness ~15% (C$1.5M).
- Cash C$9.9M; virtually debt free; two production facilities owned outright (appraised >C$15M).
- Market cap ~C$29.9M (C$0.07).
- No Zoya, Musaffa or ShariaPortfolio rating found for LABS.
Frequently asked questions
Is MediPharm Labs (LABS) halal?
Our October 2026 screen gives MediPharm Labs (LABS) a FAIL. About 15% of its Q2 2026 revenue came from Canadian adult-use (recreational) cannabis, above the ~5% de-minimis screen, and cannabis is its core business across medical and adult-use channels.
Why did MediPharm Labs fail the business gate?
MediPharm is a pharmaceutical-grade cannabis company: GMP-certified extraction, purified concentrates, APIs and derivative products. In Q2 2026, C$1.5M of C$10.0M revenue (~15%) came from Canadian adult-use + wellness, i.e. recreational cannabis. That exceeds the ~5% de-minimis screen applied to non-compliant revenue.
Does MediPharm's medical cannabis business make it halal?
No, not under this screen. Over 80% of revenue comes from regulated medical channels, but ~15% is recreational (adult-use) cannabis, which exceeds the ~5% de-minimis screen, and cannabis is the company's core business. Interpretations differ among scholars; this page reports facts only.
What about MediPharm's debt and interest income?
Both are moot for the overall result. The company is virtually debt free with C$9.9M cash at June 30, 2026, so the debt gate would pass; interest income is not separately disclosed in the Q2 2026 materials. The FAIL comes from the business gate alone.
Where can I find more healthcare stock screeners?
See our full list of stock screeners at halal-stock-verdicts.html, which covers every company screened so far.
Sources
Screened 2026-10-01 from published company figures and market data. Figures change; this page is educational, not financial advice and not a religious ruling.